KFF health tracking poll May 2024: The publics use and views of GLP-1 drugs, KFF (2024) Discontinuation and reinitation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity, JAMA Network (2025) Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks, Obesity Pillars (2024) Medication adherence and characteristics of patients who spend less on basic needs to afford medications, Journal of the American Board of Family Medicine (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity, JAMA Network (2021) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes, JAMA Network (2022) Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery, Obesity (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Because semaglutide only stimulates insulin release when blood glucose is already elevated, the risk of dangerous hypoglycemia is extremely lowa feature that makes it safer than older insulin secretagogues
[41] This effect can be useful in treating bed wetting and loss of bladder control
Do not use Wegovy (semaglutide) if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Thymosin beta-4 promotes angiogenesis, wound healing, and hair growth